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Abstract
In view of the evidence linking plasma high density lipopro-
tein (HDL)-cholesterol levels to a protective effect against
coronary artery disease and the widespread use of fibrates
in the treatment of hyperlipidemia, the goal of this study
was to analyze the influence of fibrates on the expression of
apolipoprotein (apo) A-Il, a major protein constituent of
HDL. Administration of fenofibrate (300 mg/d) to 16 pa-
tients with coronary artery disease resulted in a marked
increase in plasma apo A-Il concentrations (0.34±0.11 to
0.45+0.17 grams/liter; P < 0.01). This increase in plasma
apo A-Il was due to a direct effect on hepatic apo A-Il
production, since fenofibric acid induced apo A-Il mRNA
levels to 450 and 250% of control levels in primary cultures
ofhuman hepatocytes and in human hepatoblastoma HepG2
cells respectively. The induction in apo A-Il mRNA levels
was followed by an increase in apo A-Il secretion in both
cell culture systems. Transient transfection experiments of
a reporter construct driven by the human apo A-Il gene
promoter indicated that fenofibrate induced apo A-II gene
expression at the transcriptional level. Furthermore, several
other peroxisome proliferators, such as the fibrate, Wy-
14643, and the fatty acid, eicosatetraynoic acid (ETYA),
also induced apo A-Il gene transcription. Unilateral dele-
tions and site-directed mutagenesis identified a sequence ele-
ment located in the J-site of the apo A-Il promoter mediat-
ing the responsiveness to fibrates and fatty acids. This ele-
ment contains two imperfect half sites spaced by 1
oligonucleotide similar to a peroxisome proliferator respon-
sive element (PPRE). Cotransfection assays showed that the
peroxisome proliferator activated receptor (PPAR) trans-
activates the apo A-Il promoter through this AII-PPRE. Gel
retardation assays demonstrated that PPAR binds to the
AlI-PPRE with an affinity comparable to its binding affinity
to the acyl coA oxidase (ACO)-PPRE. In conclusion, in
humans fibrates increase plasma apo A-Il concentrations
by inducing hepatic apo A-Il production. Apo A-Il expres-
sion is regulated at the transcriptional level by fibrates and
fatty acids via the interaction of PPAR with the AII-PPRE,
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thereby demonstrating the pivotal role of PPAR in control-
ling human lipoprotein metabolism. (J. Clin. Invest. 1995.
96:741-750.) Key words: gene regulation * hypolipidemic
drugs * hyperlipidemia * peroxisome proliferation ' nuclear
hormone receptors
Introduction
Apolipoprotein (apo) A-I and apo A-II are the major protein
constituents of high density lipoproteins (HDL), the plasma
levels of which are inversely correlated with the incidence of
coronary artery disease. Apo A-fl exists in plasma as a homodi-
mer linked by an intradisulfide bond at residue 6 (1). The apo
A-II protein sequence (1), cDNA sequence (2-5), and geno-
mic structure (5-8) are known and the human gene has been
localized on chromosome 1 (9-12). In man and other mam-
mals, such as rats and mice, apo A-Il is mainly produced by
the liver, and to a much lesser extent, by the intestine ( 13, 14).
The transcription of apo A-Il requires the synergistic action of
factors, binding to a set of elements in the distal and proximal
promoter (sites A to N) (15-20), as well as in the first intron
of its gene (21). The association, reported in certain mouse
strains, between elevated apo A-Il levels and increased HDL
size and HDL-cholesterol levels suggest that the plasma concen-
tration of apo A-II might affect HDL structure and function
(22, 23). Apo A-Il may furthermore compete for the binding
of HDL to the putative HDL receptor (24). Recent in vivo
studies demonstrate that overexpression of mouse apo A-II in
transgenic mice enhances the development of atherosclerotic
lesions (25, 26), whereas overexpression of human apo A-Il
in human apo A-I transgenic mice leads to a reduced protection
against atherosclerosis (27). This in vivo effect is consistent
with the in vitro observations of a decreased capacity of apo A-
II to stimulate cholesterol efflux (28), and lecithin-cholesterol
acyltransferase activity (29), and suggests that apo A-II might
reduce the protective effects of HDL against atherosclerosis.
This hypothesis is further supported by the differential effects
on the development of atherosclerosis of the two main lipopro-
tein (Lp) particles composing HDL, LpA-I, containing only
apo A-I, and LpA-I:A-II, containing both apo A-I and A-II.
Numerous data suggest that LpA-I plays the crucial role in the
protection against atherosclerosis, whereas the LpA-I:A-II is
less efficient (30).
Fibrates, frequently used hypolipidemic agents, affect HDL
metabolism in man (31-33). These drugs belong to a group of
chemicals called peroxisome proliferators, which also contain,
besides fibrates, fatty acids, certain herbicides, and phtalate ester
plasticizers. In rodents, all these compounds induce peroxisome
proliferation (34-37) and hepatomegaly, which may ultimately
lead in these animals to hepatocarcinogenesis after prolonged
administration (38, 39). The peroxisome proliferation caused
PPAR Mediates Induction of apo A-II by Fibrates 741
J. Clin. Invest.
) The American Society for Clinical Investigation, Inc.
0021-9738/95/08/0741/10 $2.00
Volume 96, August 1995, 741-750
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI118118
by these agents is, at least in part, the result of a transcriptional
induction of enzymes of the ,3-oxidation pathway (40-45).
Lately, several studies have emphasized the importance of a
group of transcription factors, called peroxisome proliferator
activated receptors (PPARs),' in mediating this transcriptional
activation process (46-54). At present four distinct PPARs
have been described a, /3, y, 6 (47, 54). PPARs are members
of the superfamily of nuclear hormone receptors, which after
ligand activation, regulate the expression of genes containing
specific response elements, called peroxisome proliferator re-
sponse elements (PPREs) in their regulatory sequences (55,
56). Functional PPREs have been characterized in several of
the genes encoding enzymes involved in the peroxisomal /3-
oxidation pathway, such as acyl-coA oxidase (ACO) and the
trifunctional enzyme (55-60), in the cytochrome P450 4A6
gene (61, 62), in the 3-hydroxy-3-methylglutaryl-coA synthase
gene (63), in the medium-chain acyl-coA dehydrogenase gene
(64), and in the aP2 gene (52). Recently, we also identified a
functional PPRE in the 5' upstream regulatory sequences
(URS) of the apolipoprotein A-I gene (65).
In previous studies we analyzed the effects of fibrate treat-
ment on apo A-II gene expression in rodents (66). Given the
pivotal role of apo A-II in HDL physiology, we initiated more
detailed studies to investigate, first, the effects of fibrates on
human apo A-II plasma concentrations and expression and, sec-
ond, to elucidate the molecular mechanisms underlying the reg-
ulation of the apo A-II gene by fibrates. In this report, we
demonstrate that fibrates increase plasma concentrations and
hepatic production of apo A-I1 in man. Furthermore, we show
that this effect is due to the induction of apo A-II gene expres-
sion at the transcriptional level in the hepatocyte. Finally, we
show that this effect of fibrates is mediated through binding of
the nuclear hormone receptor PPAR to a PPRE, localized in
the J-site of the 5 'URS of the apo A-I1 gene.
Methods
Materials. Fenofibric acid was a kind gift of Dr. A. Edgar (Fournier
Laboratories, Daix, France), pirixinic acid (Wy-14643) and tetradecyl-
thioacetic acid (TTA) were kind gifts of Dr. Sharon Burns (Wyeth-
Ayerst, Princeton, NJ) and Dr. Jon Bremer (Oslo University, Oslo,
Norway), respectively. 5,8,11,14-eicosatetraynoic acid (ETYA), be-
zafibrate, ciprofibrate, and a-linolenic acid were purchased from Sigma
Chemical Co. (St. Louis, MO).
Human subjects and treatments. Patients with angiographically doc-
umented coronary artery disease were screened biochemically and hema-
tologically to exclude disorders likely to produce secondary hyperlipid-
emia (67). Diabetes mellitus, gout, renal, or hepatic disease constituted
specific exclusion criteria. 16 male subjects, corresponding to these
criteria and aged between 40 and 60 yr, were treated for 8 wk with
fenofibrate 300 mg daily (Laboratoires Fournier, Daix, France). Fasting
blood samples were drawn before and after treatment. Plasma was iso-
lated and apo A-II concentrations were measured.
Lipid measurements and apo A-II and apo Eprotein determinations.
Plasma apo A-II concentrations were determined by a noncompetitive
enzyme linked immunosorbent assay (ELISA). Briefly, polystyrene mi-
1. Abbreviations used in this paper: 5'URS, 5' upstream regulatory
sequence; ACO, acyl CoA oxidase; CAT, chloramphenicol acetyl trans-
ferase; DR-1, direct repeat spaced by 1 nucleotide; EMSA, electropho-
retic mobility shift assay; ETYA, 5,8,11,14-eicosatetraynoic acid;
PPAR, peroxisome proliferator activated receptor; PPRE, peroxisome
proliferator response element; TTA, tetradecylthioacetic acid.
crotiter plates were coated with a mixture of three monoclonal antibodies
to human apo A-Il (G02, G03, G013). Duplicate plasma samples were
diluted 1:10,000 and 1:7,000 with phosphate saline and were added to
the wells along with standards and controls. After incubation, apo A-TI
antibodies conjugated to peroxidase were added. Color development
was performed with the addition of substrate (o-phenylenediamine di-
chloride). The plates were read at 492 nm on a microtiter plate reader.
Human apo A-H in culture medium of primary human hepatocytes or
HepG2 cells was measured by ELISA using the same procedure as for
plasma. Human apo E in culture medium (diluted 1:5 and 1:10 with
phosphate saline) of primary human hepatocytes and HepG2 cells was
measured as previously described (68).
Cloning and construction of recombinant plasmids. A 3-Kb HindIII
fragment containing the apo A-I1 gene promoter was cloned from a
human placenta genomic DNA library in Charon 4A (a kind gift from
Dr. Stehelin). A fragment containing the -911/+160 sequence of the
apo A-I1 promoter was excised by BglI digestion, blunted, HindIII
digested and subsequently cloned into the HindIII and blunted XbaI
sites of pBLCAT5 (69). This construct was designated -911/ + 160AII-
CAT. The basal promoter (16) (-210/+160) was obtained by PCR-
amplification using -911/+160AII-CAT as template, a -210/-198
oligo containing a 5' XbaI cloning site (5'-gactctagaTGTACCCCC-
TTA-3') and an internal CAT oligo as primers. The PCR product was
digested with XbaI and BamHI and cloned into pBLCAT5 to give -210/
+ 160AII-CAT. The distal enhancer region, containing footprints N-I
( -911 /-653) (19), was prepared by AluI digestion of the -911 /+ 160
HindIII-BamHI fragment and subsequently subcloned upstream of the
basal promoter into -210/+160A11-CAT, which was PstI digested,
blunted, and then HindIII digested. The N-J, N-K and N-L 3' distal
enhancer deletion fragments were obtained by PCR amplification using
respectively a -708/-722 oligo (with a 5' PstI cloning site; 5 '-ggaagc-
tgcAGAGGCTTCTACCAG-3'), a -735/-751 oligo (with a 5' XbaI
cloning site; 5'-cgttctagAGGCACCTGGTCATTTG-3'), and a -773/
-803 oligo (5 '-gatctAGTGATTAGCCAATATTGAGTCAGCAGG-
GGC-3'). These fragments were digested and subsequently cloned up-
stream of the basal promoter in -210/+160AII-CAT using the corre-
sponding restriction sites.
Site-directed mutagenesis of the J-site PPRE was accomplished us-
ing the Amersham oligonucleotide-directed in vitro mutagenesis system
based on the method of Nakamaye and Eckstein (70) and a mutated
-741/-711 oligo (5'-GGTGCCTTCAAGCTTTACTCTGGTAGA-
AGCC-3'), which was annealed to the single-stranded -911/+160
template cloned into the M13-mpl8 phage.
The Jw, and Jmt oligonucleotides containing bases -737 to -715 of
the apo A-II gene promoter were cloned into the BamHI/BglII sites of
pIC20H (71), digested with HindIII and subcloned upstream of the
thymidine kinase (TK) promoter in pBLCAT4 (69) to generate
Jw,-TKCAT, (Jw,)3-TKCAT (respectively containing 1 and 3 copies of
the Jwt-site) and Jmt-TKCAT (containing one copy of the Jmt-site).
The following expression vectors were used. A CMV-/3-gal vector,
described by MacGregor and Caskey (72), was used as an internal
control for transfection efficiency in mammalian cells. The expression
vectors pSG5-mPPARa (a kind gift of Dr. S. Green, Zeneca, UK) (46)
and pSG5-haPPARy (53), used in transfections, have been described
elsewhere. The haPPARy and mRXRa were used to synthesize the
respective proteins (47, 53, 73).
Cell culture. The human hepatoma cell line, HepG2, was obtained
from E.C.A.C.C. (Porton down, Salisbury, U.K.). HepG2 and HeLa
cells were maintained in Dulbecco's modified Eagle's minimal essential
medium, supplemented with 10% fetal calf serum at 37°C in a humidi-
fied atmosphere of 5% C02/95% air. Medium was changed every other
day. For experiments, cells were changed to fresh medium containing
10% calf serum delipoproteinized by ultracentrifugation in KBr (1.21
grams/ml) and subsequently treated with AG-1-X8 resin (BioRad) plus
activated charcoal. Stimuli were dissolved in DMSO (fibrates) or etha-
nol (fatty acids) and added to the medium at the indicated concentrations
and periods of time. Control cells received vehicle only. In the case of
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fatty acids, preincubation with medium was carried out for 45 min
at 370C.
Human liver specimens were collected from physically healthy
multiorgan donors for transplantation at the Moscow Medical Center,
who died after severe traumatic brain injury. Permission to use the
remaining, not transplanted part of donor liver for scientific research
was obtained from the Ministry of Health of the Russian Federation.
Hepatocytes were obtained by a two-step collagenase perfusion as pre-
viously described (74). Cells were resuspended in minimal essential
medium with Earl's salts (GIBCO-BRL, Paisley, UK) supplemented
with 10% FCS, 2 mM L-glutamine, 50 mg/ml gentamycine, seeded at
a density of 1.5 x 105 cells/cm2 in 60-mm plastic culture dishes coated
with 20 mg rat tail collagen type I (Sigma Chemical Co.) and incubated
in a humified atmosphere of 5% C02/95% air at 370C. Medium was
renewed after a 4-h adhesion period. After 20 h the medium was dis-
carded and fenofibric acid (in DMSO, final concentration 0.5% vol/
vol) was added at the indicated concentrations in serum-free medium.
No morphological differences in cell adhesion or cell toxicity (deter-
mined by the MTT [tetrazoliumi colorimetric test)(75) were observed
between control and treated hepatocytes.
RNA analysis. RNA from cells was prepared as described by Chomc-
zynski and Sacchi (76). Northern blot hybridizations and quantification
of total cellular RNA were performed as described previously (66).
Apo A-fl mRNA was measured using a human apo A-Il cDNA clone
(11). A human GAPDH cDNA clone (77) was used as control. All
probes were labeled by random priming (Boehringer Mannheim). Quan-
titative analysis was performed by scanning densitometry (BioRad
GS670 densitometer).
Transient transfections and expression assays. Transfections in
HepG2 cells were performed at 50-60% confluency by the calcium
phosphate coprecipitation procedure with a mixture of plasmids which
contained in addition to the reporter and expression vector(s), 0.5 Jsg
of CMV-P-gal expression vector as a control for transfection efficiency.
All samples were complemented to an equal total amount of DNA.
After 4 h cells were washed with PBS, and incubated for another 16 h
with fenofibric acid, other fibrates or fatty acids in fresh medium con-
taining 5% calf serum delipoproteinized by ultracentrifugation in KBr
(1.21 grams/ml) and subsequently treated with AG-1-X8 resin (Bio-
Rad) plus activated charcoal. CAT activity was determined on cell
extracts as described by Gorman et al. (78). Autoradiographs were
quantified by liquid scintillation counting and results were normalized
for transfection efficiency. Transfection efficiencies were normalized
with the ,B-galactosidase activity assay (Promega Protocols and Applica-
tions Guide, 2nd Edition). Transfection experiments were performed at
least three times.
Electrophoretic mobility shift assays (EMSA). To study the AII-
PPRE identified in the 5' regulatory region of the apo A-Il gene, a
synthetic double-stranded oligonucleotide spanning nucleotides -737
to -715 of the human apo A-Il gene S' URS was used (5 '-gatCCTTCA-
ACCTTTACCCTGGTAGA-3'), as well as an oligonucleotide con-
taining 2 point mutations into the potential AII-PPRE (5'-gatCCTT-
CAAGCIrrACTCTGGTAGA-3') (Ai-PPREmt). A 30-bp double-
stranded oligonucleotide containing the PPRE of the rat ACO gene and
spanning from -575 to -548 (5'-GATCCCGAACGTGACCTTTGT-
CCTGGTCCC-3') was used as a control PPRE.
haPPARy (53) and mRXRa (73) proteins were synthesized in vitro
using the rabbit reticulocyte lysate system (Promega). Molecular weight
and the quality of the in vitro translated proteins were verified by SDS-
PAGE. 2 yl of PPAR and/or RXR were preincubated in a total volume
of 20 j1 for 15 min on ice with 2.5 jtg poly(dI:dC) and 1 jtg herring
sperm DNA in TM buffer (10 mM Tris-HCl, pH 7.9,40 mM KCl, 10%
glycerol, 0,05% NP-40 and 1 mM DTT). For competition experiments,
increasing amounts of cold oligonucleotide ACO-PPRE, AIl-PPRE^,
or Ail-PPRE,, (from 50- to 400-fold molar excess) were included just
before adding T4-polynucleotide kinase end-labeled oligonucleotide.
After 15 min of incubation at room temperature, DNA-protein com-
plexes were separated by electrophoresis on a 4% polyacrylamide gel
in 0.25x TBE buffer at 40C (79).
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Figure 1. Plasma apo
A-Il concentrations in-
crease upon treatment
with fenofibrate in 16
subjects with coronary
artery disease. Plasma
was obtained from sub-
jects with angiographi-
cally documented coro-
nary artery disease before
and after an 8 week treat-
ment with 300 mg/d of
fenofibrate. Apo A-Il
concentrations were
measured as described
under materials and
methods. The mean±SD
before and after treat-
ment is indicated by the
solid circles (P < 0.01
by Wilcoxon's test).
Statistical analysis. Data are expressed as the mean±SD unless
stated otherwise. Student's t-, ANOVA, and Wilcoxon tests were used
to analyze for statistical significance.
Results
Plasma apo A-II concentrations increase afterfibrate treatment
in man. To analyze whether fibrate treatment alters serum apo
A-Il concentrations in man, 16 subjects with angiographically
proven coronary heart disease, were treated with 300 mg of
fenofibrate daily for a period of 8 wk. Fasting blood was taken
immediately before and after completion of the treatment proto-
col and apo A-Il concentrations were measured. Treatment with
fenofibrate significantly increased apo A-II concentrations from
0.34±0.11 grams/liter to 0.45±0.17 grams/liter (P < 0.01 by
Wilcoxon's test) (Fig. 1).
Fibrates increase apo A-II mRNA and protein secretion in
primary human hepatocytes and in the human hepatoblastoma
cell line HepG2. To study the mechanism of induction of plasma
apo A-Il concentrations in vivo, the regulation of apo A-fl
expression by fibrates was studied in two different human cell
culture systems. First, the effects of fenofibrate was studied
using primary cultures of human hepatocytes. Addition of feno-
fibric acid for 24 h to the culture media induced the apo A-Il
mRNA levels already near-maximally at a dose of 50 jLM (Fig.
2 A). A maximal fivefold stimulation over control was observed
at 500 jtM of fenofibric acid (Fig. 2 A). No change in acyl
coA oxidase (ACO) or GAPDH mRNA levels could be ob-
served under these conditions (not shown and Fig. 2 A). The
induction of apo A-II mRNA levels was accompanied after 48
h by a significant increase in apo A-Il secretion in the culture
medium (Fig. 2 B). In contrast, apo E secretion in the culture
medium remained constant under these conditions (Fig. 2 B).
Next, it was investigated whether fenofibric acid also in-
duces apo A-Il mRNA levels and protein secretion in the human
hepatoblastoma cell line HepG2. When HepG2 cells were
treated with 500 ,uM fenofibric acid, apo A-Il mRNA levels
increased to 154 and 248% of control values at 24 and 48 h,
respectively (Fig. 3, A and B). To verify whether this induction
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Figure 2. Fenofibric acid increases apo A-I1
A O CON mRNA levels (A) and protein secretion (B)
c a n s - _ _ * FF in primary cultures of adult human hepato-
_150 - cytes. (A) Human hepatocytes were isolated
1 8S - _ and treated for 24 h with the indicated doses
of fenofibric acid (FF). 5 ,ug of total RNA
APOA-1-_100 was subjected to electrophoresis, transferredPOIl to a nylon membrane and hybridized to apo
A-H (top panel) or GAPDH (bottom panel)
50v cDNA as described in materials and methods.
GAPDH- The position of the 18 S and 28S rRNA bands
are indicated on the left of the top panel. (B)
0 50 100050 0 _ Human hepatocytes were treated for 48 hr
Concentration FF (x 10o M) APO A-Il APO E with fenofibric acid (FF, 500 pM) or solvent(CON, DMSO). Apo A-TI and apo E pro-
tein concentrations were measured in medium as described in materials and methods. Values are expressed relative to controls and represent the
mean±SD of three points. Statistically significant differences (t-test) are indicated by an asterisk.
in apo A-II mRNA levels was accompanied by increased apo
A-II protein secretion, apo A-TI concentration was measured in
the culture medium of control and fenofibric acid treated cells.
Therefore, dose-response experiments were performed in
HepG2 cells and apo A-II secretion was determined after 24 or
48 h of fenofibric acid (Fig. 3 C). Apo A-II concentrations in
medium already increased significantly after 48 h at a dose of
100 1iM fenofibric acid. A further increase was observed at 250
uM both at 24 and 48 h and maximal effects were attained with
500 ,uM fenofibric acid. At this concentration apo A-II secretion
was respectively 3.1- and 3.6-fold higher at 24 and 48 h of
fenofibric acid treatment.
The increase in apo A-II gene expression after fibrates is
due to an increase in apo A-Il gene transcription. To study
whether fibrates induce apo A-II gene expression at the tran-
scriptional level the human apo A-II promoter was cloned in
front of the chloramphenicol acetyltransferase (CAT) reporter
gene. This construction was transfected in the human hepa-
toblastoma cell line HepG2 and cells were treated with different
doses of fenofibric acid. A viral promoter (Rous sarcoma virus)
driven CAT plasmid (RSV-CAT) was transfected as a control.
Apo A-II promoter driven CAT activity increased 1.5-fold
at 250 and 500 MM fenofibric acid (Fig. 4 A). The potent fibrate
derivative Wy-14643 induced apo A-II promoter activity to
195±15% and 180±18% at concentrations of 30 and 100 pM
respectively (Fig. 4 A). By contrast the RSV-driven CAT activ-
ity remained unchanged under these conditions (DMSO:
100±11%; FF 500 MM: 93+13%). These results clearly indi-
cate that the increase in apo A-Il production in human liver
after fibrates occurs at the transcriptional level.
To investigate whether the increased expression of the apo
A-II promoter after fenofibrate was a particular feature of fi-
brates or a more general effect of peroxisome proliferators and
fatty acids, the effects of different peroxisome proliferators on
apo A-II gene transcription were analyzed after transient trans-
fection of the -911/ + 160A-II-CAT construct (Fig. 5). When
different fibrates were compared, the expression of the apo
A-II promoter was induced by fenofibrate (1.5-fold) and by the
potent PPAR activator, Wy-14643 (1.8-fold) (80). The sulfur-
containing fatty acid analogue tetradecylthioacetic acid (TTA)
did not affect apo A-II promoter activity, whereas the arachi-
donic acid derivative 5,8,11,14-eicotetraynoic acid (ETYA)
provoked a strong increase of apo A-II promoter transcription
(twofold). The nonmodified fatty acid, a-linolenic acid did not
o o24 hr
*-48 hr
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Figure 3. Fenofibric acid induces
apo A-II mRNA and protein se-
cretion in the human hepatoblas-
toma cell-line, HepG2. (A)
HepG2 cells were treated for 24
or 48 h with fenofibric acid (500
jLM) or solvent (DMSO). Apo
A-II and GAPDH mRNA levels
tI - 1 gwere measured as described in
50- GAD-r;materialsand methods. Values are
expressed relative to solvent
_ _ .-.treated controls and represent the
APO A-Il GAPDH CON FF 0 100 250 500 mean±SD of four points. Statisti-
Concentration FF (x 10-6 M) cally significant differences (t-
test, P < 0.01) are indicated by
an asterisk. (B) Northern blot analysis. 5 pg of total RNA isolated from HepG2 cells treated during 48 h with 500 pM fenofibric acid (FF) or
vehicle (CON) was subjected to electrophoresis, transferred to a nylon membrane and hybridized to apo A-II (top panel) or GAPDH (bottom
panel) cDNA as described in materials and methods. The position of the 18S and 28S rRNA bands are indicated on the left of the top panel. (C)
HepG2 cells were treated for 24 (open circles) or 48 h (closed circles) with fenofibric acid (in DMSO) at the indicated concentrations. Apo A-II
measurements were performed as described under materials and methods. Values represent the mean+SD of three points per dose. Statistically
significant differences from control (ANOVA, P < 0.001) are indicated by an asterisk.
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Concentration Fenofibric Acid (x 10-6 M)
influence apo A-LI promoter driven CAT activity. This clearly
indicates that the induction of apo A-LI promoter activity is not a
general effect, but is a property restricted to specific peroxisome
proliferators.
Delineation of a PPRE in the regulatory sequences of the
apo A-lI gene. Next, studies were performed to delineate the
cis-acting regulatory sequences within the 5' URS of the apo
A-IL gene, implicated in the induction of apo A-IL gene tran-
scription by peroxisome proliferators, such as fenofibric acid
and fatty acids. Since apo A-LI promoter activity is largely
determined by elements in the distal enhancer (elements I to
N) ( 19), 3' site by site recurrent deletions of the distal enhancer
P150 *
(100
( 50
Figure 5. Influence of different fibrates and fatty acids on apo A-H
promoter transcription. Hep-G2 cells were transiently transfected with
the -911/ + 160AII-CAT plasmid and subsequently treated with fenofi-
bric acid (FF; 500 MM), bezafibrate (BF; 500 MM), ciprofibrate (CIF;
500 MM), Wy-14643 (100 MM), tetradecylthioacetic acid (TTA; 80
MM), 5,8,11,14-eicosatetraynoic acid (ETYA; 80 AM), a-linolenic acid
(LA; 100 MM) or vehicle. CAT activity was measured and expressed
(mean±SD) as described in materials and methods. Statistically sig-
nificant differences from controls (ANOVA, P < 0.001) are observed
between values followed by different letters.
Figure 4. Fenofibric acid and Wy-14643 induce apo
A-LI gene expression at the transcriptional level via
the apo A-fl promoter. (A) HepG2 cells were tran-
siently transfected with -911/+160A11-CAT plas-
mid and treated for 16 h with the indicated doses of
fenofibric acid (FF) or Wy-14643 dissolved in
DMSO. CAT-activity was measured and expressed
(mean±SD) as described under materials and meth-
ods. Statistically significant differences from con-
trols (ANOVA, P < 0.05) are indicated by an aster-
isk. (B) Representative CAT assay showing the
dose-dependent effects of fenofibric acid on apo
A-LI promoter activity.
region were cloned in front of the basal apo A-II promoter and
their regulation by fenofibrate was compared with the entire
apo A-Il regulatory region contained in -911/+160AII-CAT
after transfection in HepG2 cells (Fig. 6). Fenofibric acid treat-
ment induced the CAT activity of the construct containing the
entire regulatory region (-911/+160), as well as constructs
containing sites N-I and N-J. However, upon deletion of site J
(plasmids containing only sites N-K and N-L) the induction
of CAT activity by fenofibric acid was completely abolished.
Similarly, cotransfection of the pSG5-mPPARa expression vec-
tor only activated the constructs containing the J-site, which are
capable of responding to fenofibric acid (Fig. 6). Addition of
fenofibric acid to cells cotransfected with pSG5-mPPARa and
the entire promoter construct (-911/+160AII-CAT) did not
result in a further stimulation relative to cotransfection of pSG5-
mPPARa by itself. However, additive effects of fenofibric acid
and PPAR were evident for the constructs containing sites N-J
and N-I in front of the basal apo A-H promoter. These data
suggest the presence of a potential PPRE in the J-site, a regula-
tory element located between -734 and -716 bp from the
transcription start site of the human apo A-II gene, which has
previously been shown to bind liver nuclear proteins by foot-
print assay.
Interestingly, the J-site contains two imperfect copies of a
motif related to the consensus steroid hormone receptor binding
half-site TGACCT arranged as direct repeats with 1 nucleotide
spacing (DR-1). To investigate whether this DR-1 located in
the J-site represents the functional response element mediating
the observed effects of PPAR on apo A-LI gene transcription,
the DR-1 site was mutated (Fig. 7 A) and its activity was
compared to the activity of the wild-type (wt) construct ( -91 1 /
+ 160AII-CAT) transfected in HepG2 cells (Fig. 7, B and D).
Mutation of the J-site DR-I sequence not only resulted in a loss
of inducibility of apo A-LI promoter regulation by PPAR and
fenofibric acid, but also in a strong decrease in baseline level
CAT activity (Fig. 7 D). This decrease in basal CAT activity
suggests that the J-site not only mediates the transcriptional
response to PPAR and peroxisome proliferators, but also is a
strong site driving the basal expression of the apo A-II promoter.
To prove that the J site could function as a PPRE in front
of a heterologous promoter, the J, site was cloned as a mono-
and trimer in front of the heterologous thymidine kinase (TK)
promoter to generate the construct J,-TK-CAT (Fig. 7A). Upon
cotransfection of these constructs with mPPARa into HepG2
cells it was evident that the J site could transmit PPAR activa-
tion to this heterologous promoter (Fig. 7 C). The TK-CAT
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Figure 6. The induction of apo
A-H gene transcription by fibrates
and PPAR is mediated by the apo
A-II promoter J site in the apo
A-II promoter. HepG2 cells were
transfected with different apo
A-II gene promoter deletion con-
structs, schematically depicted in
A, in the presence of cotransfected
mPPARa or pSG5 vector plasmid.
Cells were treated with fenofibric
acid (500 /M) or vehicle
(DMSO) and CAT activity
was measured and expressed
(mean±SD) as described in
Methods. Values statistically dif-
ferent from vehicle treated, pSG5
cotransfected apo A-TI promoter
constructs are indicated by an as-
terisk.
vector or the Jmt-TK-CAT were only marginally activated by
mPPARa (Fig. 7 C). However, in HepG2 cells PPAR displays
a substantial transactivation potential even in the absence of
exogenously added activators (see Figs. 6 B and 7 B). There-
fore, to determine whether PPAR mediates the activation of apo
A-II gene transcription by fibrates, HeLa cells were transfected
with the (Jwt)3-TK-CAT construct in the presence or not of
cotransfected PPAR and the influence of fenofibrate or Wy-
14643 treatment was analyzed next (Fig. 8). Addition of feno-
fibrate or Wy-14643 alone did not activate (Jwl)3-TK-CAT ex-
pression in HeLa cells. Cotransfection of PPAR resulted in a
nearly twofold activation and treatment with fenofibrate and
Wy-14643 resulted in a substantial further increase in CAT
activity (3- and 8-fold, respectively) (Fig. 8). In contrast, fi-
brate treatment, whether in the presence of cotransfected
mPPARa or not, did not activate Jm,-TK-CAT expression in
HeLa cells (data not shown). Taken together, these data
strongly argue that the J site of the apo A-II gene contains a
bona-fide PPRE (AII-PPRE), which mediates the fenofibrate
induction of apo A-II gene transcription through PPAR activa-
tion.
PPAR/RXR heterodimers bind to the AII-PPRE in the J site
of the apo A-Il gene. Next, it was investigated whether PPAR
could bind to the AII-PPRE by electrophoretic mobility shift
assays (EMSA). Incubation of a double-stranded oligonucleo-
tide corresponding to the J site (Jw,) and spanning sequences
from -737 to -715 relative to the transcription initiation site
of the apo A-II gene with in vitro produced haPPARy and
mRXRa resulted in the formation of a retarded complex (Fig.
9). Similar binding data were obtained when xPPARa was used
instead of haPPARy, and mRXRa was replaced by mRXR/3
(data not shown), demonstrating that the AII-PPRE was capa-
ble of binding different PPAR/RXR heterodimers. By contrast,
haPPARy homodimers were incapable of binding to the J,, site
(Fig. 9, lane 4). On a labeled double-stranded oligonucleotide
containing the mutated AII-PPRE (AIV-PPREm,) no binding of
haPPAR-y and mRXRa heterodimers was observed, thereby
confirming and extending the results of our transfection experi-
ments (Fig. 9, lane 8).
To demonstrate that the proteins binding to the AII-PPRE
were identical to those binding to the classical ACO-PPRE,
cross competition experiments were performed next. In a first
experiment, it was tested whether cold ACO-, AII-PPREwt- and
AII-PPREmt- oligonucleotides could compete with the binding
of haPPARy/mRXR/3 heterodimers to the labeled AIIWPPRE
oligonucleotide (Fig. 9 lanes 11-22). Both the ACO and AII-
PPREWt sequences competed, whereas the AII-PPREmt did not
compete with the binding of haPPARy/mRXRa heterodimers
to the AII-PPRE,^. Interestingly, the competition was as effi-
cient with the cold ACO-PPRE and AII-PPRE~t oligonucleo-
tides, suggesting that the AII-PPRE is a strong PPRE. In a
second experiment, cross competition was performed using
ACO-PPRE as a probe (data not shown). Also in this experi-
ment equivalent molar ratios of cold ACO or All-PPREt oligo-
nucleotide could prevent haPPARy/mRXRa heterodimers from
binding to the ACO-PPRE. In contrast, cold AII-PPREm. oligo-
nucleotide could not compete for the binding of haPPAR'y/
mRXRa heterodimers from binding to the ACO-PPRE.
Discussion
In view of the evidence linking elevated levels of HDL-choles-
terol to a protective effect against the development of coronary
artery disease and the widespread use of fibrates in the treatment
of diet-resistant hyperlipidemia, one of the goals of our research
was to determine whether fibrates regulate the expression of
apo A-IT, one of the major protein constituents of HDL, and to
understand the molecular mechanisms underlying its regulation.
Despite the beneficial effects of these drugs on apo B-containing
lipoproteins, results from most of the clinical studies indicate
that fibrates favor the occurrence of a HDL profile consisting
of an augmentation of LpA-I/A-II particles, which are less
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Figure 8. PPAR expression is required for activation of the apo A-Il J-
site by fibrates. (A) HeLa cells were transfected with the (J,t,)3TKCAT
plasmid in the presence of cotransfected mPPARa or pSG5 vector plas-
mids. Cells were treated with fenofibric acid (FF; 250 MM), Wy-14643
(Wy; 100 ,M) or vehicle (DMSO) and CAT activity was measured
and expressed as described under materials and methods. Statistically
significant differences from control (pSG5) are indicated by an asterisk.
(B) CAT assay demonstrating the effects of cotransfection of mPPARa
and treatment with fenofibric acid (FF; 250 MM) and Wy-14643 (Wy;
100 MM) on (J,)3TKCAT expression in HeLa cells.
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Figure 7. The J site in the apo A-Il promoter contains a functional
PPRE: effects of point mutation in the J site and effects of the J site
on a heterologous promoter. (A) Schematic representation of the con-
structs J-TK-CAT and -911/+160AII-CAT. The wild type as well as
the mutated apo A-Il J-sites are indicated (Jw and Jmt, respectively).
B. Effects of fenofibric acid and PPAR on the expression of apo A-Il
promoter containing a wild-type (-911 /J/ + 160AII-CAT) or mutant
(-911 /Jmt/ +160AI-CAT) AIl PPRE. HepG2 cells were transfected
with the indicated plasmids in the presence of cotransfected mPPARa
or pSG5 vector plasmids. Cells were treated with fenofibric acid (500
zMM) or vehicle (DMSO) and CAT activity was measured and expressed
as described under materials and methods. Statistically significant differ-
ences from control (pSG5) are indicated by an asterisk. (C) PPAR
activates the wild-type (J,,,), but not the mutant (Jmt) J-site when cloned
upstream of the heterologous thymidine kinase promoter (TK) promoter.
HepG2 cells were transfected in the presence of cotransfected mPPARa
or pSG5 vector plasmids. Cells were treated with fenofibric acid (500
MM) or vehicle and CAT activity was measured and expressed as de-
scribed under materials and methods. Statistically significant differences
from control (pSG5 cotransfected constructs) are indicated by an aster-
isk. (D) CAT assay demonstrating the effects of Wy-14643 (30 MM)
or cotransfection of mPPARa on the -91 /J,,/+l160AI-CAT and
-91 1 /Jmt'+ 160-CAT vectors.
efficient cholesterol acceptors than LpA-I particles (31 ). Inter-
estingly, the clinical data in this paper demonstrate that the
change towards an altered HDL profile after fibrate treatment,
is associated with a marked increase in apo A-Il plasma concen-
trations. Furthermore, we demonstrate that the increase in apo
A-II protein concentration after fenofibrate is caused by a direct
effect of fibrates on hepatic apo A-II production, and is therefore
not merely a consequence of alterations in plasma lipid concen-
trations. In fact, treatment of primary human hepatocytes or
HepG2 cells with fenofibric acid, the active form of fenofibrate,
results in a corresponding increase in apo A-Il gene expression
and protein production. This increase in apo A-LI mRNA steady
state levels suggested that regulatory sequences in the apo
A-Il gene are functionally implicated in this induction. Results
from transfection experiments showed that fenofibrate has an
overall positive effect on the activity of the apo A-II promoter.
Recently, it has been shown that a group of transcription factors,
termed PPARs, belonging to the nuclear hormone receptor gene
superfamily (46, 47), mediate the effects of peroxisome prolif-
erators, such as fibrates and various fatty acids, on gene expres-
sion (47, 48). Consistent with this hypothesis, we demonstrated,
by cotransfection of a PPAR expression vector, that PPAR me-
diates the fenofibric acid-dependent transcriptional activation
of the apo A-H gene. It is noteworthy that the apo A-Il promoter
is also transcriptionally activated by PPAR in the absence of
fenofibric acid or other exogeneous stimuli. This could be due
to the inherent activity of the transcriptional activating functions
of PPAR (81) or, alternatively and perhaps more likely, to
the presence of (a) natural ligand(s), constitutively activating
PPAR in these cells. It can, however, not be excluded that
both mechanisms act together, since fibrates could potentiate
the positive effect of PPAR on the truncated apo A-II promoter
constructs. By using unilateral 3' deletions of the apo A-I1 distal
enhancer region, we localized the responsive region in the J
site (19). This site was found to contain two imperfect copies
of a motif related to the consensus steroid hormone receptor
half-site TGACCT arranged with a spacing of 1 nucleotide (or
DR- 1). Previous studies have shown that this J element forms
two DNA-protein complexes in hepatocyte nuclear extracts,
termed AIIJl and AIIJ2, the last of which has some similarities
with NF-BA-1 (82, 83). Furthermore, several orphan nuclear
receptors, such as HNF-4, EAR2, EAR3, and ARP- 1, have been
shown to interact with this J site (20, 82). In fact, HNF-4
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Figure 9. PPAR/RXR heterodimers bind to
the J-site wild-type (All-PPRE,), but not to
the mutated AHl-PPRE (All-PPREmt). (A)
Gel retardation assays were performed on
end-labeled AH-PPRE,, or AI-HPPREmt oli-
gonucleotides in the presence of in vitro tran-
scribed/translated haPPAR-y (PPAR),
mRXRa (RXR) or unprogrammed reticulo-
cyte lysate as described under materials and
methods in the presence ( + ) or not (- ) of
100-fold molar excess of unlabeled wild-type
(comp wt) or mutant (comp mt) oligonucle-
otide (none = no extract added). (B) Com-
petition experiments for binding to in vitro
transcribed/translated haPPARy/mRXRa
were performed using end-labeled All-
PPREW, oligonucleotide in the absence (-)
or presence of 50, 100, 200 and 400-fold
molar excess of cold AII-PPRE,, AII-
PPREmt or ACO oligonucleotide.
induces, whereas EAR-2, EAR-3, and ARP-l reduce apo A-II
gene transcription upon binding to this element (20). In view
of the binding of multiple nuclear hormone receptors to this J
element, it was no surprise that PPAR could also interact with
this element. Indeed, site-directed mutagenesis experiments
demonstrated that this DR-I motif mediates the effects of PPAR
and fibrates on apo A-II gene expression, whereas EMSA exper-
iments indicated that PPAR/RXR heterodimers bind to the All-
PPRE. Moreover, cross-competition experiments indicated that
the All-PPREt binds PPAR with a similar affinity as the classi-
cal ACO-PPRE. These data hence implicate unequivocally
PPAR in the response of the apo A-II gene to fibrate hypolip-
idemic drugs. In view of the proposed role of PPARs in mediat-
ing the effects of nutrition on gene expression it is tempting to
speculate that nutritional effects on apo A-II gene expression
also might be mediated via transcription factors belonging to
the PPAR family. The induction of apo A-II promoter activity
by certain fatty acid derivatives is an argument in support of
this hypothesis. More detailed experiments to study the effects
of various nutritional compounds on apo A-II expression are
currently undertaken in our laboratory.
In contrast to the increase in apo A-TI mRNA levels in
human hepatocytes and hepatoma cells, hepatic apo A-II mRNA
levels decrease after in vivo administration of fibrates to rodents
(66). However, in rat liver the decrease in apo A-TI mRNA
levels was not associated with altered transcription activity of
the apo A-II gene, whereas in human liver increased apo A-H
mRNA levels are linked to PPAR-mediated induction of apo
A-II gene transcription. The different mechanisms involved in
this species-specific opposite regulation of apo A-II mRNA
levels are unclear at present, but several possible hypothesis
can be forwarded. First, differences may exist between species
in either the cis-acting elements, involved in these regulatory
processes, or in the general promoter structure, leading to the
absence of transcriptional regulation in rats, but not in humans.
Second, qualitative and/or quantitative differences in trans-act-
ing factors present in rodent or human liver may contribute to
species-specific responses to certain agents. This is, however,
less likely to explain the differential response to fibrates. In
fact, it is clearly established that both rat and man produce
multiple PPARs, the transcription factors involved in mediating
the genomic response to peroxisome proliferators. Finally, spe-
cies-specific metabolic differences could also affect the re-
sponse to fibrates. In rodents these compounds act by inducing
the expression of several genes coding for peroxisomal enzymes
which results in a strong proliferation of peroxisomes and an
extreme hepatomegaly (40, 41, 44, 84). In contrast to rodents,
the expression of the ACO gene remains constant in human
hepatocytes treated with fenofibrate (85), thereby indicating
that fibrates have no or only a very limited capacity to induce
peroxisomal enzymes in humans, as has been suggested pre-
viously by several authors (34-37). Since it is hypothesized
that, at the cellular level, fibrates act indirectly probably by
affecting intermediary steps of intracellular lipid metabolism
(34), it is conceivable that species-specific differences in intra-
cellular metabolic responses to fibrates may differently affect
gene expression via transcriptional or post-transcriptional regu-
latory mechanisms.
From these data, as well as from previous studies from
our and other laboratories, it becomes increasingly evident that
PPARs not only play an important role in the control of intracel-
lular lipid metabolism and /3-oxidation, but also have a wide
impact on lipid transport and lipoprotein physiology. When one
considers HDL metabolism, it is evident that PPAR not only
controls expression of apo A-II, but also the production rate of
apo A-I, the other major protein component of HDL. In previous
studies, we have indeed shown that PPAR and its activators
have also a complex effect on the expression of apo A-I. On
the one hand, fibrates exert a negative and probably PPAR-
independent effect on apo A-I gene transcription mediated by
sequence elements located in the apo A-I basal promoter. On
the other hand, this effect is counteracted by a PPAR-dependent
positive effect mediated by a PPRE located in the A-site of the
apo A-I promoter (65). In man this delicate interplay of regula-
tion through the PPAR binding A site and the apo A-I basal
promoter can result in a variable regulation of the entire apo
A-I promoter depending upon the cellular context. Fibrates and
PPAR not only have major effects on the metabolism of HDL
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particles, but they also affect the metabolic fate of apo B con-
taining particles. In fact, we showed that fibrates diminish he-
patic production of apo C-III, a mechanism which may lie at
the basis of the hypotriglyceridemic action of these compounds
(85). Indeed, due to the reduced apo C-III concentration, both
LPL-mediated lipolysis as well as, receptor-mediated clearance
of triglyceride-rich particles will be improved, resulting in low-
ering of plasma triglyceride concentrations.
In conclusion, the results from these studies show that in
humans apo A-II plasma concentrations increase upon treatment
with fibrates, as a result of a PPAR-mediated induction of apo
A-II gene transcription leading to an increase in hepatic apo A-
II production. The regulation of the apo A-II gene by fibrates
is another example indicating that, unlike in rodents, fibrates/
PPAR can modulate gene expression in humans without the
concurrent induction of peroxisomal enzymes.
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